Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities

Journal of Intellectual Disability Research

Volumn 52, Issue 2, 2008, Pages 132-140

  Ruedrich, Stephen L ^a   Swales, T P ^a   Rossvanes, C ^b   Diana, L ^b   Arkadiev, V ^c   Lim, K ^d  

^a METROHEALTH MEDICAL CENTER   (United States)

^b Youngstown Developmental Center   (United States)

^c Department of Psychiatry ^*

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aggression; Atypical antipsychotics; Intellectual disability; Self injurious behaviour

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; GLUCOSE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGGRESSION; ANXIETY DISORDER; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; METABOLIC DISORDER; MOOD DISORDER; PATIENT MONITORING; PSYCHOSIS; REVIEW; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; RETROSPECTIVE STUDIES; RISPERIDONE; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME;

EID: 38049152595     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2007.00981.x     Document Type: Review

References (39)

1. Advokat C. D., Mayville E. A. & Matson J. L. (2000) Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medication in persons with mental retardation. Research in Developmental Disabilities 21, 75-84.
2. Aman M. G. & Madrid A. (1999) Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 5, 253-63.
3. Aman M. G. & Gharabawi G. M., for the Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients with Mental Retardation and Developmental Disabilities (2004) Treatment of behavior disorders in mental retardation: Report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Journal of Clinical Psychiatry 65, 1197-210.
4. American Diabetes Association (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
5. Brylewski J. & Duggan L. (1999) Antipsychotic medication for challenging behaviour in people with intellectual disability: A systemic review of randomized controlled trials. Journal of Intellectual Disability Research 43, 360-71.
6. Buckley P. F. (1999) New antipsychotic agents: Emerging clinical profiles. Journal of Clinical Psychiatry 1 (Suppl.), 12-7.
7. Casey D. (2004) Dyslipidemia and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65 (18 Suppl.), 27-35.
8. Cheng-Shannon J., McGough J. J., Pataki C. & McCracken J. T. (2004) Second generation antipsychotic medication in children and adolescents. Journal of Child and Adolescent Psychopharmacology 14, 372-94.
9. Cohen S., Glazewski R., Khan S. & Khan A. (2001) Weight gain with risperidone among patients with mental retardation: Effect of calorie restriction. Journal of Clinical Psychiatry 62, 114-6.
10. Cohen S., Fitzgerald B., Okos A., Khan S. & Khan A. (2003) Weight, lipids, and glucose; and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry 64, 60-2.
11. Fletcher R., Loschen E., Stavrakaki C. & First M. (eds) (2007) Diagnostic Manual-Intellectual Disability: A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disabilities. NADD Press, Kingston, NY.
12. Friedlander R., Lazar S. & Klanchik J. (2001) Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Canadian Journal of Psychiatry 46, 741-5.
13. Hellings J. A., Zarcone J. R., Carndall K., Wallace D. & Schroeder S. R. (2001) Weight gain in a controlled study of risperidone in children, adolescent and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology 11, 229-38.
14. Janowsky D. S., Barnhill L. J. & Davis J. M. (2003) Olanzapine for self-injurious aggressive and disruptive behaviors in intellectually-disabled adults: A retrospective open-label, naturalistic trial. Journal of Clinical Psychiatry 64, 1258-65.
15. Janssen L. P. (2006) New Indication for Risperdal (risperidone). Available at: http://risperdalautism.com (retrieved 14 April 2007).
16. Kane J. M., Leucht S., Carpenter D. & Docherty J. P. (2003) Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. Journal of Clinical Psychiatry 64 (12 Suppl.), 5-19.
17. Lieberman J. A., Stroup T. S., McEvoy J. G., Swartz M. S., Rosenheck R. A., Perkins D. O., Keefe R. S., Davis S. M., Davis C. E., Lebowitz B. D., Severe J. & Hsiao J. K. (2005) Effectiveness of antipsychotic drugs in patient with chronic schizophrenia. New England Journal of Medicine 353, 1209-23.
18. McDougle C. J., Scahill L., Aman M. G., McCracken J. T., Tierney E., Davies M., Arnold L. E., Posey D. J., Martin A., Ghuman J. D., Shah B., Chuang S. Z., Swiezy N. B., Gonzalez N. M., Hollway J., Koenig K., McGough J. J., Ritz L. & Vitiello B. (2005) Risperidone for the core symptom domains of autism: Results from the study by the autism network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry 162, 1142-8.
19. McKee J. R., Bodfish J. W., Mahorney S. L., Heeth W. L. & Ball M. P. (2005) Metabolic effects associated with atypical antipsychotic treatments in the developmentally disabled. Journal of Clinical Psychiatry 66, 1161-8.
20. Magliano D. J., Shaw J. E. & Zimmet P. Z. (2006) How to best define the metabolic syndrome. Annals of Medicine 38, 34-41.
21. Meltzer H. Y. (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clinical Neurosciences 3, 64-75.
22. Mikkelsen E. J. & McKenna L. (1999) Psychopharmacologic algorithms for adults with developmental disabilities and difficult-to-diagnose behavioral disorders. Psychiatric Annals 29, 302-14.
23. Naber D., Karow A. & Lambert M. (2005) Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatrica et Neurologica Scandinavica Supplementum 427, 29-34.
24. Robertson J., Emerson E., Pinkney L., Caesar E., Felce D., Meek A., Carr D., Lowe K., Knapp M. & Hallam A. (2005) Treatment and management of challenging behavior in congregate and non-congregate community-based supported accommodation. Journal of Intellectual Disability Research 49, 63-72.
25. Rothbard A., Murrin M. R. & Jordan N. (2005) Effects of antipsychotic medication on psychiatric services, utilization, and cost. Journal of Mental Health Policy and Economics 8, 83-93.
26. Royal College of Psychiatrists (2001) The Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/ Mental Retardation. Occasional Paper 48. Gaskell Press, London.
27. RUPP (Research Units on Pediatric Psychopharmacology) Autism Network (2005) Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6months. American Journal of Psychiatry 162, 1361-9.
28. Rush A. J. & Frances A. (2000) Expert Consensus Guideline Series: treatment of psychiatric and behavioral problems in mental retardation. American Journal of Mental Retardation 105, 159-228.
29. Schroeder S. R., Bouras N., Ellis C. R., Reid A. H., Sandman C., Werry J. S. & Wisniewski H. (1998) Past research on psychopharmacology of people with mental retardation and developmental disabilities. In: Psychotropic Medication and Developmental Disabilities: The International Consensus Handbook (eds Reiss, S. & Aman, M. G.), pp. 19-30. The Ohio State University Nisonger Center, Columbus, OH.
30. Shedlack K. J., Hennen J., Magee C. & Cheron D. M. (2005) Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and co-morbid psychiatric disorders. Journal of Clinical Psychiatry 66, 52-62.
31. Simon E. W., Blubaugh K. M. & Pippidis M. (1996) Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Mental Retardation. 34, 359-66.
32. Tandon R., Milner K. & Jibson M. D. (1998) Antipsychotics from theory to practice: Integrating clinical and basic data. Journal of Clinical Psychiatry 60 (8 Suppl.), 21-8.
33. Tsouris J. A., Cohen I. L., Patti P. J. & Korosh W. M. (2003) Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Journal of Clinical Psychiatry 64, 1081-90.
34. Williams H., Clarke R., Bouras N., Martin J. & Holt G. (2000) Use of the atypical antipsychotics olanzapine and risperidone in adults with intellectual disability. Journal of Intellectual Disability Research 44, 164-9.
35. Wirshing D. A. (2004) Schizophrenia and obesity: Impact of antipsychotic medications. Journal of Clinical Psychiatry 65 (18 Suppl.), 13-26.
36. Yan E. G. & Munir R. M. (2004) Regulating and ethical principles in research involving children and individuals with developmental disabilities. Ethics and Behavior 14, 31-49.
37. Zajecka J. & Goldstein C. (2003) The side-effect profiles of antipsychotic medications. Primary Psychiatry 10, 78-91.
38. Zarcone J. R., Hellings J. A., Crandall K., Reese R. M., Marquis J., Fleming K., Shores R., Williams D. & Schroeder S. R. (2001) Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal of Mental Retardation 106, 525-38.
39. Zhang P. L., Santos J. M., Newcomer J., Pelfrey B. A., Johnson M. C. & de Erausquin G. A. (2004) Impact of atypical antipsychotics on quality of life, self report of symptom severity, and demand for services in chronically psychotic patients. Schizophrenia Research 71, 137-44.